Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 18, 2015, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $424.57 to $433,700,000.00.

Highlighted Stocks Traded by Insiders:

Salesforce.com (CRM) - FREE Research Report

Tomlinson Lawrence, who is Director at Salesforce.com, sold 800 shares at $62.58 on Feb. 18, 2015. Following this transaction, the Director owned 26,632 shares meaning that the stake was reduced by 2.92% with the 800-share transaction.

Benioff Marc, who is Chairman of the Board & CEO at Salesforce.com, sold 25,000 shares at $62.43 on Feb. 18, 2015. Following this transaction, the Chairman of the Board & CEO owned 38.3 million shares meaning that the stake was reduced by 0.07% with the 25,000-share transaction.

Conway Craig, who is Director at Salesforce.com, sold 500 shares at $62.58 on Feb. 18, 2015. Following this transaction, the Director owned 9,484 shares meaning that the stake was reduced by 5.01% with the 500-share transaction.

Norton Burke F, who is EVP and Chief Legal Officer at Salesforce.com, sold 5,000 shares at $62.32 on Feb. 18, 2015. Following this transaction, the EVP and Chief Legal Officer owned 37,701 shares meaning that the stake was reduced by 11.71% with the 5,000-share transaction.

The shares most recently traded at $62.66, up $0.34, or 0.55% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 187,400
  • 12-Week # shares sold: 657,165
  • 24-Week # shares sold: 1.6 million

The average volume for Salesforce.com has been 4.4 million shares per day over the past 30 days. Salesforce.com has a market cap of $39.2 billion and is part of the technology sector and computer software & services industry. Shares are up 6.22% year-to-date as of the close of trading on Wednesday.

salesforce.com, inc. provides enterprise cloud computing solutions to various businesses and industries worldwide. Currently, there are 24 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings

Scroll to Continue

TheStreet Recommends

rates Salesforce.com as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Salesforce.com Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Omnicell (OMCL) - FREE Research Report

Petersmeyer Gary S, who is Director at Omnicell, sold 670 shares at $35.41 on Feb. 18, 2015. Following this transaction, the Director owned 17,695 shares meaning that the stake was reduced by 3.65% with the 670-share transaction.

The shares most recently traded at $35.30, down $0.11, or 0.31% since the insider transaction. Historical insider transactions for Omnicell go as follows:

  • 4-Week # shares sold: 670
  • 12-Week # shares sold: 10,393
  • 24-Week # shares sold: 21,823

The average volume for Omnicell has been 199,200 shares per day over the past 30 days. Omnicell has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 6.19% year-to-date as of the close of trading on Wednesday.

Omnicell, Inc. provides automation solutions for medication and supply management in healthcare worldwide. The company operates in two segments, Acute Care and Non-Acute Care. The company has a P/E ratio of 42.6. Currently, there are 3 analysts who rate Omnicell a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMCL - FREE

TheStreet Quant Ratings

rates Omnicell as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Omnicell Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Monmouth Real Estate Investment (MNR) - FREE Research Report

Miller Kevin S., who is Chief Financial Officer at Monmouth Real Estate Investment, bought 45 shares at $11.14 on Feb. 18, 2015. Following this transaction, the Chief Financial Officer owned 23,064 shares meaning that the stake was boosted by 0.19% with the 45-share transaction.

The shares most recently traded at $11.51, up $0.37, or 3.21% since the insider transaction. Historical insider transactions for Monmouth Real Estate Investment go as follows:

  • 4-Week # shares bought: 224
  • 12-Week # shares bought: 1,964
  • 24-Week # shares bought: 4,200

The average volume for Monmouth Real Estate Investment has been 195,600 shares per day over the past 30 days. Monmouth Real Estate Investment has a market cap of $668.8 million and is part of the financial sector and real estate industry. Shares are up 4.61% year-to-date as of the close of trading on Wednesday.

Monmouth Real Estate Investment Corporation (MREIC) is a real estate investment trust. It owns, manages, and leases properties to investment-grade tenants on long-term leases. The firm invests in the public equity and real estate markets of the United States. The stock currently has a dividend yield of 5.21%. The company has a P/E ratio of 48.0. Currently, there is 1 analyst who rates Monmouth Real Estate Investment a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNR - FREE

TheStreet Quant Ratings

rates Monmouth Real Estate Investment as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Monmouth Real Estate Investment Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null